Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
accessed, adequacy, adoptedASC, afflicted, Australia, brand, branded, certainty, creation, Dainippon, deadline, desvenlafaxine, disability, discount, double, doughnut, duration, earliest, EC, Education, EMA, expansion, Fanapt, Fanapy, fifteen, footnote, forfeited, galson, gap, HCL, hole, intercompany, IRS, issuable, kelly, Latuda, lowest, lurasidone, magnitude, medicinal, microsphere, milano, nighttime, ninteen, nondeductible, oldest, past, permanent, PPACA, Pristiq, rebate, rebated, reconcile, relevant, Relprevvtm, Silenor, Sumitomo, supplemental, sweeping, synchronization, temporary, Viibryd, vilazodone, vincent
Removed:
Acadia, adjusting, agonist, Amex, bifeprunox, brian, carryforward, ceased, committed, composed, consolidate, consummation, conversion, converted, currency, deducting, EDB, effected, feature, final, force, functional, GAAP, halak, indiplon, modified, Neurocrine, nominal, nonfinancial, obtainable, pimavanserin, prevailing, principally, prospective, recently, receptor, reclaimed, registration, regular, resale, reverse, Silenortm, Singapore, Solvay, split, translated, translation, underwriting, variety, vested
Filing tables
Filing exhibits
Related press release
VNDA similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-133368, No. 333-138070, No. 333-141571, No. 333-148924, No. 333-156995, No. 333-164567 and No. 333-171962) and on Form S-3 (No. 333-171963) of Vanda Pharmaceuticals Inc. of our report dated March 10, 2011 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Baltimore, Maryland
March 10, 2011
March 10, 2011